Publisher
Springer Science and Business Media LLC
Reference70 articles.
1. Revi M. Alzheimer’s Disease Therapeutic Approaches. Adv Exp Med Biol. 2020;1195:105–16.
2. Liu KY, Howard R. Can we learn lessons from the FDA’s approval of aducanumab? Nat Rev Neurol. 2021;17:715–22.
3. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer’s Disease. N Eng J Med. 2022;388:1631–2.
4. Guiloff AE, Rudge P. Amyloid antibody therapy for early-stage Alzheimer’s disease: a critical review of three recent trials. J Neurol. 2024. https://doi.org/10.1007/s00415-024-12361-w.
5. Høilund-Carlsen PF, Alavi A, Castellani RJ, Neve RL, Perry G, Revheim ME et al. Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers? Int J Mol Sci. 2024;25. https://doi.org/10.3390/ijms25073892.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献